Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children
Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children
The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will:
Undergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.
This is a prospective study evaluating the impact of intraoperative RADA16 application on the postoperative course following pediatric tonsillectomy as it relates to pain, bleeding, readmission, and use of a rescue analgesic (ex., oxycodone). We propose a randomized controlled trial whereby patients undergoing tonsillectomy would either receive a standard analgesic regimen (postoperative acetaminophen and NSAIDs plus oxycodone as a supplemental analgesic) versus intraoperative RADA16 application plus a standard analgesic regimen.
Inclusion Criteria:
Children aged 3-17 years undergoing tonsillectomy +/- adenoidectomy CPT codes
Exclusion Criteria:
wayne.hsueh@rutgers.edu973-972-4588
gf345@njms.rutgers.edu973-972-2309
wayne.hsueh@rutgers.edu9739722548